GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
Speeding up access to new drugs for Cystic Fibrosis: Considerations for clinical trial design and delivery
Theranostics by testing CFTR modulators in patient-derived materials: the current status and a proposal for subjects with rare CFTR mutations
Inhaled antibiotic use is associated with Scedosporium/Lomentospora species isolation in cystic fibrosis
